Member Info for Brand

VN is a market I know well and contrary to what others have posted on here, has the potential to be a big market for SNG. 100m population, a huge now well established middle class w genuine purchasing power, and a venerated aged population that would be ideal candidates for SNG.

To be clear, I'm not trying to say VN is where SNG will make their billions, but it's representative of so many other 'new' economies that are often overlooked in the west. Good to see SSH getting press here.

I guess RM rejoined twitter ;-)

Mr Costs I understand you have quite a large holding so I understand the sentiment. But all of that independent, peer reviewed data about interferons (funded by the NIH) the relationship between covid and our inf response etc, is what will get sng over the line with regulators when coupled with sprinter results.

https://twitter.com/Synairgenplc/status/1478699824459485184?t=OE04qxOWEVEMRG_gSxhKvw&s=19

Put much more elequantly than me Skippy - apologies Bob if you were indeed being genuine. So much f**kery about atm.

Bob. It's analytics, not black magic. Read a book.

This article from a couple weeks back certainly hints at the same Elsol.

https://www.fiercepharma.com/pharma/astrazeneca-weighs-spinning-division-covid-19-vaccine-antibodies-into-separate-company

'Separating the business would be an answer to earlier concerns that tapping into COVID-19 might have been a distraction for the company. But senior executives are evaluating various possibilities with advisers and could eventually decide against a spinoff, the people said, according to the news service.

AZ unveiled the new division a month ago. To be led by Iskra Reic, AZ’s executive vice president of Europe and Canada, the new unit is basically a viral respiratory infectious disease franchise. It houses the company’s COVID-19 vaccine Vaxzevria and investigational COVID antibody ****tail AZD7442 plus nasal spray flu vaccine Flumist, ex-U.S. rights to respiratory syncytial virus (RSV) drug Synagis and an investigational RSV therapy called nirsevimab that’s partnered with Sanofi.

RELATED: With FDA scrutinizing its data, AstraZeneca shows durability of COVID-preventing antibodies

During a conference call with reporters last month, AstraZeneca CEO Pascal Soriot suggested the move to migrate the portfolio into a new unit was “business as usual” and did not elaborate on whether he plans further investment to boost the department or to sell it off in the future.'

I recall someone saying on here that the rules around RNS mean the company could in theory share their trial data with potential partners before informing the market.. is that right?

Telegraphed.

What's the CW for valuing a pharmaco? Think I remember someone on here saying 5 X annual sales? Have I got it right?

Andybe - please do show me where I've said 4th Jan above. I've had a good look and all I can see is you (and of course your other accounts) making an a**e of yourself.

Again, I know it pays the bills but I strongly advise you delete your account. This kinda of job can't be good for your mental health...

Andybe - only account on this board by my memory that said anything about Jan 4th was you. When you were building your narrative, as per below:

Post
Brand

Wed 17:02

Posts: 329

Price: 202.00

Oh Andybe, wasn't it just a couple of months ago you were spouting absolute drivel and claiming to be a woman?

We can all see what your doing, putting on this SP warrior persona, while dropping all sorts of hints about cashing out at £5 or £10 (while contributing nothing of substance of course)

Your game is weak man. Delete your account.

Recommend (6)Report Post
Andybe4

Wed 17:02

Posts: 340

Price: 202.00

Brand, if you’re wrong and results don’t come early (like Jan 4th), you clearly have a motive. Trying to get everyone to put their money in the share before January 4th, hmmm,

I call bull**** on Jan 4th. You don’t have a clue.

Recommend (1)Report Post
Andybe4

Wed 17:09

Posts: 340

Price: 202.00

You delete your account you muppet, telling everyone to buy in before January 4th. You don’t have a clue.

RecommendReport Post

Go on then Andy Be - what's your comments on this... Or can you not grasp simple science?

Regarding Long Covid

https://www.ft.com/content/ed89cad2-6f82-44f0-b01d-c4490e4a7372

'Sir Stephen Holgate, University of Southampton professor and co-founder of Synairgen, a company that is creating Covid-19 antiviral medication, said MRI scans had also shown inflamed organs.

“The body turns on itself as a result of all this inflammation during the Covid period and attacks its own tissue."

H/T to @1985muenchen on twitter for the find

You reckon they spent 3 billion on Activ P2 trials? This is the initial announcement of a huge pot of money to support the development of antivirals. Now that Interferons are classified as antivirals, sng is eligible for some of those sweet US dollars. It's quite simple actually.

Note the most important word below: manufacturing

'Thanks to the American Rescue Plan, the Biden Administration is investing more than $3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as part of the Biden Administration’s whole-of-government strategy to develop the next generation of COVID-19 treatments.'

Bit of background on this one.... study conducted at UCLA and funded by the NIH - also an institution in India - Looks pretty damn good.

Published By The American Association of Immunologists, Inc.
Print ISSN 0022-1767
Online ISSN 1550-6606
History
Received July 29, 2021
Accepted October 27, 2021
Published online December 21, 2021.

ARTICLE VERSIONS

Older version (November 24, 2021 - 07:56).
You are viewing the most recent version of this article.
Copyright & Usage Copyright © 2021 by The American Association of Immunologists, Inc.

AUTHOR INFORMATION

Beibei Wu*,1, Arunachalam Ramaiah†,‡,1, Gustavo Garcia Jr.§, Spyridon Hasiakos*,¶, Vaithilingaraja Arumugaswami§,?,#,2 and Sonal Srikanth*,

*Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA;

†Department of Ecology and Evolutionary Biology, University of California, Irvine, Irvine, CA;

‡Tata Institute for Genetics and Society, Center at inStem, Bangalore, Karnataka, India

FUNDING
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

HHS | NIH | National Eye Institute (NEI)

One thing it means is sng is able to access funding from this...

https://www.niaid.nih.gov/news-events/biden-administration-invest-3-billion-american-rescue-plan-part-covid-19-antiviral

'As part of the plan announced today, the NIH will evaluate, prioritize and advance antiviral candidates to Phase 2 clinical trials, using current and expanded contract resources and the NIH’s National Center for Advancing Translational Sciences laboratories to de-risk early stage development with sponsors and guide candidates along development paths. The plan provides more than $300 million for research and lab support, nearly $1 billion for preclinical and clinical evaluation, and nearly $700 million for development and manufacturing through NIAID and BARDA.'

A very detailed study just posted on the public Reddit board.

https://www.jimmunol.org/content/208/1/74

The kicker....

'The key finding of this study is that the baseline IFN-ß level regulated by ORAI1-mediated Ca2+ signaling is critical for priming the cellular antiviral state, thereby determining host resistance to SARS-CoV-2 infection. A recent phase 2 clinical trial of inhaled, nebulized IFN-ß to treat people with COVID-19 resulted in accelerated recovery, supporting localized delivery of IFN-I as a potential prophylactic and therapeutic agent against COVID-19 (47). The therapeutic effect of IFN-I targeting SARS-CoV-2 infection may be partly derived from boosting tonic IFN-I signaling. Our findings may help develop novel therapeutic methods to combat SARS-CoV-2 infection by demonstrating that pharmacological enhancement of baseline cytoplasmic [Ca2+] improved host resistance to SARS-CoV-2. Furthermore, the current study emphasizing the crucial role of tonic IFN-I signaling in resistance to SARS-CoV-2 infection may guide future identification of vulnerable populations and targeted therapies at boosting tonic IFN-I signaling.'

Happy new year :)

Underated post this...

'There was a comment about various governments wanting a 'heads up' after a few skipped heartbeats when our 'results' RNS landed (it was actually the company results, not p3). The implication is there that 'they' are primed and ready.'

From the moment RM said this I couldn't help but thinking this was BJ and our inept UK govt, scared they would miss out on the positive PR...

Go on lads, spill the beans....